2126744-35-0 Usage
Uses
Used in Pharmaceutical Industry:
4-((6-chloro-3,4-dihydroquinolin-1(2H)-yl)methyl)-N-hydroxybenzamide is used as a small molecule inhibitor for targeting specific protein-protein interactions in cellular pathways. Its application is based on its ability to modulate cellular processes by inhibiting the activity of certain enzymes or proteins, which can be beneficial in the treatment of various diseases.
Used in Chemical Research:
In the field of chemical research, 4-((6-chloro-3,4-dihydroquinolin-1(2H)-yl)methyl)-N-hydroxybenzamide serves as a valuable compound for studying the structure-activity relationships of various biologically active molecules. Its unique structure allows researchers to investigate the effects of specific functional groups on the compound's interactions with target proteins or enzymes.
Used in Drug Development:
4-((6-chloro-3,4-dihydroquinolin-1(2H)-yl)methyl)-N-hydroxybenzamide is used as a lead compound in the development of new drugs for various therapeutic applications. Its chemical properties and potential to modulate cellular processes make it a promising candidate for further optimization and development into a more potent and selective drug molecule.
Used in SW-100 HDAC6 Inhibitor Applications:
4-((6-chloro-3,4-dihydroquinolin-1(2H)-yl)methyl)-N-hydroxybenzamide is used as an HDAC6 or SIRT2 inhibitor for treating PACS1 and PACS2 syndromes. Its application is based on its ability to restore Golgi morphology in a cell, which is crucial for the proper functioning of cellular processes and the treatment of these specific syndromes.
Check Digit Verification of cas no
The CAS Registry Mumber 2126744-35-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,2,6,7,4 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2126744-35:
(9*2)+(8*1)+(7*2)+(6*6)+(5*7)+(4*4)+(3*4)+(2*3)+(1*5)=150
150 % 10 = 0
So 2126744-35-0 is a valid CAS Registry Number.
2126744-35-0Relevant academic research and scientific papers
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model
Shen, Sida,Picci, Cristina,Ustinova, Kseniya,Benoy, Veronick,Kutil, Zsófia,Zhang, Guiping,Tavares, Maurício T.,Pavlí?ek, Ji?í,Zimprich, Chad A.,Robers, Matthew B.,Van Den Bosch, Ludo,Ba?inka, Cyril,Langley, Brett,Kozikowski, Alan P.
, p. 4810 - 4840 (2021/05/07)
Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
Kozikowski, Alan P.,Shen, Sida,Pardo, Marta,Tavares, Maurício T.,Szarics, Dora,Benoy, Veronick,Zimprich, Chad A.,Kutil, Zsófia,Zhang, Guiping,Ba?inka, Cyril,Robers, Matthew B.,Van Den Bosch, Ludo,Eubanks, James H.,Jope, Richard S.
, p. 1679 - 1695 (2019/01/04)
Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures. Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacological a
TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS
-
Paragraph 0174; 0176, (2017/09/08)
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, tr
